- Home
- SLXN vs PRPO Comparison
SLXN vs PRPO Comparison
Compare SLXN & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- PRPO
- Stock Information
- Founded
- SLXN 2008
- PRPO N/A
- Country
- SLXN Israel
- PRPO United States
- Employees
- SLXN N/A
- PRPO N/A
- Industry
- SLXN
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- SLXN
- PRPO Industrials
- Exchange
- SLXN NYSE
- PRPO Nasdaq
- Market Cap
- SLXN 4.3M
- PRPO 10.3M
- IPO Year
- SLXN N/A
- PRPO N/A
- Fundamental
- Price
- SLXN $1.28
- PRPO $6.94
- Analyst Decision
- SLXN Strong Buy
- PRPO
- Analyst Count
- SLXN 1
- PRPO 0
- Target Price
- SLXN $9.00
- PRPO N/A
- AVG Volume (30 Days)
- SLXN 9.6M
- PRPO 16.2K
- Earning Date
- SLXN 03-25-2025
- PRPO 03-28-2025
- Dividend Yield
- SLXN N/A
- PRPO N/A
- EPS Growth
- SLXN N/A
- PRPO N/A
- EPS
- SLXN N/A
- PRPO N/A
- Revenue
- SLXN N/A
- PRPO $17,411,000.00
- Revenue This Year
- SLXN N/A
- PRPO $75.18
- Revenue Next Year
- SLXN N/A
- PRPO N/A
- P/E Ratio
- SLXN N/A
- PRPO N/A
- Revenue Growth
- SLXN N/A
- PRPO 31.31
- 52 Week Low
- SLXN $0.21
- PRPO $4.31
- 52 Week High
- SLXN $13.56
- PRPO $10.74
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- PRPO 46.78
- Support Level
- SLXN N/A
- PRPO $6.56
- Resistance Level
- SLXN N/A
- PRPO $7.81
- Average True Range (ATR)
- SLXN 0.00
- PRPO 0.75
- MACD
- SLXN 0.00
- PRPO -0.14
- Stochastic Oscillator
- SLXN 0.00
- PRPO 11.14
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.